Phase II Study of First Line Izalontamab Brengitecan Combined with Sintilimab in Patients with HER2-Negative Gastric or Gastroesophageal Junction Cancer (GC/GEJ) (ESMO Asia 2026) - Oct 1, 2026 - Abstract #249P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • P2 data • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2
|
|
Wei He; Yuxian Bai; Jun Yao; Jufeng Wang; Wei Li; Yigui Chen; Yongli Gao; Jin Xia; Xianli Yin; Changzheng Li; Tong Xie; Jifang Gong; Daiyuan Ma; Bihui Li; Sa Xiao; Hai Zhu; Yi Zhu; Lin Shen
|